Market Research Reports and Industry Reports

Valeant Pharmaceuticals International, Inc. (VRX) - Medical Equipment - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Valeant Pharmaceuticals International Inc (Valeant) is a specialty pharmaceutical company. It carries out the development, manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada and the US. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International, Inc. (VRX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


5
List of Figures 7
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 8
Valeant Pharmaceuticals International, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 9
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 10
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 11
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 12
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deal Details 17
Asset Purchase 17
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 17
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 18
Venture Financing 19
AcuFocus Raises Funds Through Series F Financing 19
Private Equity 21
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 21
Water Street Healthcare Partners Acquires OraPharma 22
Partnerships 23
Namtall Enters into Licensing Agreement with Valeant Pharma 23
Bausch & Lomb Enters Into Licensing Agreement With Cirle 24
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 25
Bausch & Lomb Enters Into Licensing Agreement With UltraVision 26
Synergetics Enters Into Licensing Agreement With Alcon Labs 27
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 28
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 29
Valeant Pharmaceuticals International Partners With Living Proof 30
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 31
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 32
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 33
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 34
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 35
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 36
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 37
Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 38
Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 39
Synergetics USA Enters Into Co-Development Agreement With Retinal Solutions 40
Cutera Enters Into An Agreement With Obagi Medical Products 41
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 42
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 44
Salix Pharma Enters Into Licensing Agreement With Photocure For Lumacan 45
Equity Offering 47
Bausch & Lomb Withdraws IPO 47
Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 49
Debt Offering 50
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 50
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 52
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 53
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 55
Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 57
Valeant Pharma Completes Public Offering Of 6.875% Senior Unsecured Notes Due 2018 For US$1,000 Million 58
Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2020 For US$700 Million 59
Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$500 Million 61
Valeant Pharma Completes Private Placement Of Senior Unsecured Notes For US$400 Million 63
Asset Transactions 64
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 64
Stryker Acquires Neuro Portfolio Assets of Synergetics 65
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 66
Medicis Pharma Plans Sale Of LipoSonix Device 67
Stryker Completes Acquisition Of Orthopedic Assets And Worldwide Rights From Mutoh And Synergetics USA 68
Acquisition 70
Bausch + Lomb to Acquire Doctors Allergy Formula 70
Valeant Pharma Acquires Synergetics 71
Valeant Pharma to Acquire Unilens Vision 73
Synergetics Surgical Acquires Sterimedix for USD13.5 Million 74
Valeant Canada Acquires CROMA Pharma Canada 75
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 76
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 78
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 81
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 82
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 84
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 85
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 87
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 89
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 90
Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 92
Solta Medical Acquires Medicis Technologies From Medicis Pharma 93
ATON Acquires 100% Stake In OrthoScan 94
Solta Medical Completes Acquisition Of Aesthera 95
Valeant Pharmaceuticals International, Inc. - Key Competitors 96
Key Employees 97
Locations And Subsidiaries 99
Head Office 99
Other Locations & Subsidiaries 99
Recent Developments 108
Financial Announcements 108
Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 108
Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 112
Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 114
Mar 15, 2016: Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information 116
Corporate Communications 117
Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 117
Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 118
Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 119
Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 121
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 122
May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 123
May 03, 2016: Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 124
Apr 29, 2016: Valeant Announces Nominees For Election To Board Of Directors 125
Apr 25, 2016: Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 127
Mar 21, 2016: Valeant Announces CEO Succession Plan And Changes To Board Of Directors 128
Mar 09, 2016: Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board 129
Mar 02, 2016: Valeant Pharmaceuticals Announces Management Change 131
Feb 28, 2016: Valeant Pharmaceuticals Announces Management And Business Update 132
Legal and Regulatory 133
Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 133
Mar 09, 2016: Valeant And R&O Pharmacy End Litigation 134
Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition 135
Other Significant Developments 136
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 136
May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 137
Apr 13, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters 138
Mar 21, 2016: Valeant Provides Accounting And Financial Reporting Update 139
Oct 13, 2015: Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lombs Greenville Solutions Plant 142
Appendix 143
Methodology 143
About GlobalData 143
Contact Us 143
Disclaimer 143

List Of Tables


Valeant Pharmaceuticals International, Inc., Medical Equipment, Key Facts, 2015 1
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 1
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 8
Valeant Pharmaceuticals International, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 9
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 10
Valeant Pharmaceuticals International, Inc., Deals By Market, 2010 to YTD 2016 11
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 12
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 17
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 18
AcuFocus Raises Funds Through Series F Financing 19
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 21
Water Street Healthcare Partners Acquires OraPharma 22
Namtall Enters into Licensing Agreement with Valeant Pharma 23
Bausch & Lomb Enters Into Licensing Agreement With Cirle 24
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 25
Bausch & Lomb Enters Into Licensing Agreement With UltraVision 26
Synergetics Enters Into Licensing Agreement With Alcon Labs 27
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 28
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 29
Valeant Pharmaceuticals International Partners With Living Proof 30
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 31
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 32
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 33
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 34
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 35
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 36
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 37
Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 38
Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 39
Synergetics USA Enters Into Co-Development Agreement With Retinal Solutions 40
Cutera Enters Into An Agreement With Obagi Medical Products 41
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 42
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 44
Salix Pharma Enters Into Licensing Agreement With Photocure For Lumacan 45
Bausch & Lomb Withdraws IPO 47
Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 49
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 50
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 52
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 53
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 55
Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 57
Valeant Pharma Completes Public Offering Of 6.875% Senior Unsecured Notes Due 2018 For US$1,000 Million 58
Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2020 For US$700 Million 59
Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$500 Million 61
Valeant Pharma Completes Private Placement Of Senior Unsecured Notes For US$400 Million 63
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 64
Stryker Acquires Neuro Portfolio Assets of Synergetics 65
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 66
Medicis Pharma Plans Sale Of LipoSonix Device 67
Stryker Completes Acquisition Of Orthopedic Assets And Worldwide Rights From Mutoh And Synergetics USA 68
Bausch + Lomb to Acquire Doctors Allergy Formula 70
Valeant Pharma Acquires Synergetics 71
Valeant Pharma to Acquire Unilens Vision 73
Synergetics Surgical Acquires Sterimedix for USD13.5 Million 74
Valeant Canada Acquires CROMA Pharma Canada 75
4 76
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 78
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 81
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 82
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 84
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 85
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 87
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 89
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 90
Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 92
Solta Medical Acquires Medicis Technologies From Medicis Pharma 93
ATON Acquires 100% Stake In OrthoScan 94
Solta Medical Completes Acquisition Of Aesthera 95
Valeant Pharmaceuticals International, Inc., Key Competitors 96
Valeant Pharmaceuticals International, Inc., Key Employees 97
Valeant Pharmaceuticals International, Inc., Other Locations 99
Valeant Pharmaceuticals International, Inc., Subsidiaries 99

List Of Figures


Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 1
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 1
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 1
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 1
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 8
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 9
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 10
Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals by Market, 2010 to YTD 2016 11

Valeant Pharmaceuticals International Inc (VRX) - Medical Equipment - Deals and Alliances Profile.

Valeant Pharmaceuticals International Inc (Valeant) is a pharmaceutical and medical device company that carries out development, manufacture and marketing of several branded, over-the-counter (OTC) and generic drugs. The company also

USD 250View Report

Valeant OOO in Eyewear (Russia)

The future plans and expected direction of the company include intensification of its promotion and advertising activities, improvement of its cooperation with retailers and expansion of its assortment within eyewear

USD 150View Report

Valeant Pharmaceuticals International Inc (VRX) - Medical Equipment - Deals and Alliances Profile.

Valeant Pharmaceuticals International Inc (Valeant) is a pharmaceutical and medical device company that carries out development, manufacture and marketing of several branded, over-the-counter (OTC) and generic drugs. The company also

USD 250View Report

Valeant Pharmaceuticals International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Valeant Pharmaceuticals International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Valeant Pharmaceuticals International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Nov 2016
No. of Pages :143
Country :Canada
Category :Medical Devices
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube